Literature DB >> 33000143

Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection.

Katharine H D Crawford1,2,3, Adam S Dingens1, Rachel Eguia1, Caitlin R Wolf4, Naomi Wilcox4, Jennifer K Logue4, Kiel Shuey4, Amanda M Casto4, Brooke Fiala5,6, Samuel Wrenn5,6, Deleah Pettie5,6, Neil P King5,6, Alexander L Greninger7,8, Helen Y Chu4, Jesse D Bloom1,2,9.   

Abstract

Most individuals infected with SARS-CoV-2 develop neutralizing antibodies that target the viral spike protein. Here we quantify how levels of these antibodies change in the months following SARS-CoV-2 infection by examining longitudinal samples collected between ~30 and 152 days post symptom onset from a prospective cohort of 32 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about four-fold from one to four months post symptom onset. This decline in neutralizing antibody titers was accompanied by a decline in total antibodies capable of binding the viral spike or its receptor-binding domain. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B-cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Keywords:  COVID-19; RBD; SARS-CoV-2; antibody dynamics; neutralizing antibodies; spike

Year:  2020        PMID: 33000143      PMCID: PMC7543487          DOI: 10.1093/infdis/jiaa618

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

Review 1.  Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.

Authors:  Filippo Milano; Joshua A Hill; Lorenzo Iovino; Laurel A Thur; Sacha Gnjatic; Aude Chapuis
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

2.  IgG Antibodies against SARS-CoV-2 Correlate with Days from Symptom Onset, Viral Load and IL-10.

Authors:  Mary K Young; Christine Kornmeier; Rebecca M Carpenter; Nick R Natale; Jennifer M Sasson; Michael D Solga; Amy J Mathers; Melinda D Poulter; Xiao Qiang; William A Petri
Journal:  medRxiv       Date:  2020-12-07

3.  Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.

Authors:  Baweleta Isho; Kento T Abe; Michelle Zuo; Alainna J Jamal; Bhavisha Rathod; Jenny H Wang; Zhijie Li; Gary Chao; Olga L Rojas; Yeo Myong Bang; Annie Pu; Natasha Christie-Holmes; Christian Gervais; Derek Ceccarelli; Payman Samavarchi-Tehrani; Furkan Guvenc; Patrick Budylowski; Angel Li; Aimee Paterson; Feng Yun Yue; Lina M Marin; Lauren Caldwell; Jeffrey L Wrana; Karen Colwill; Frank Sicheri; Samira Mubareka; Scott D Gray-Owen; Steven J Drews; Walter L Siqueira; Miriam Barrios-Rodiles; Mario Ostrowski; James M Rini; Yves Durocher; Allison J McGeer; Jennifer L Gommerman; Anne-Claude Gingras
Journal:  Sci Immunol       Date:  2020-10-08

4.  Sero-monitoring of health care workers reveals complex relationships between common coronavirus antibodies and SARS-CoV-2 severity.

Authors:  Sigrid Gouma; Madison E Weirick; Marcus J Bolton; Claudia P Arevalo; Eileen C Goodwin; Elizabeth M Anderson; Christopher M McAllister; Shannon R Christensen; Debora Dunbar; Danielle Fiore; Amanda Brock; JoEllen Weaver; John Millar; Stephanie DerOhannessian; Ian Frank; Daniel J Rader; E John Wherry; Scott E Hensley
Journal:  medRxiv       Date:  2021-04-19

5.  A simple protein-based surrogate neutralization assay for SARS-CoV-2.

Authors:  Kento T Abe; Zhijie Li; Reuben Samson; Payman Samavarchi-Tehrani; Emelissa J Valcourt; Heidi Wood; Patrick Budylowski; Alan P Dupuis; Roxie C Girardin; Bhavisha Rathod; Jenny H Wang; Miriam Barrios-Rodiles; Karen Colwill; Allison J McGeer; Samira Mubareka; Jennifer L Gommerman; Yves Durocher; Mario Ostrowski; Kathleen A McDonough; Michael A Drebot; Steven J Drews; James M Rini; Anne-Claude Gingras
Journal:  JCI Insight       Date:  2020-10-02

6.  Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescent from COVID-19 infection.

Authors:  Catharina Gerhards; Margot Thiaucourt; Maximilian Kittel; Celine Becker; Volker Ast; Michael Hetjens; Michael Neumaier; Verena Haselmann
Journal:  Int J Infect Dis       Date:  2021-04-28       Impact factor: 3.623

7.  Evidence of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019.

Authors:  Jee-Soo Lee; So Yeon Kim; Taek Soo Kim; Ki Ho Hong; Nam-Hee Ryoo; Jaehyeon Lee; Jae Hyeon Park; Sung Im Cho; Man Jin Kim; Young-Gon Kim; Boram Kim; Ho Seob Shin; Hyeon Sae Oh; Myoung-Seock Seo; Tae-Rin Gwon; Yeonjae Kim; Jun-Sun Park; Bum Sik Chin; Wan Beom Park; Sung Sup Park; Moon-Woo Seong
Journal:  Clin Infect Dis       Date:  2020-11-21       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.